...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Clinical Microbiology >Use of aminotransferase, hepatitis C antibody, and hepatitis C polymerase chain reaction RNA assays to establish the diagnosis of hepatitis C virus infection in a diagnostic virology laboratory.
【24h】

Use of aminotransferase, hepatitis C antibody, and hepatitis C polymerase chain reaction RNA assays to establish the diagnosis of hepatitis C virus infection in a diagnostic virology laboratory.

机译：在诊断病毒学实验室中使用氨基转移酶，丙型肝炎抗体和丙型肝炎聚合酶链反应RNA分析来确定丙型肝炎病毒感染的诊断。

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Clinical and therapeutic decisions for hepatitis C virus (HCV) infection depend on factors that include documentation of past infection as well as identification of those who might benefit from antiviral chemotherapy with systemic interferon. To evaluate the ability of a diagnostic laboratory to accurately identify such patients, we compared results obtained with serum transaminase assays, two HCV antibody assays (enzyme immunoassay [EIA] and immunoblot), and a polymerase chain reaction (PCR)-based assay for HCV RNA using a group of consecutively submitted samples within our university-based diagnostic virology laboratory and sera from a population of random blood donors. One hundred percent of specimens with R values of greater than 3.0 in the HCV EIA were positive in the confirmatory immunoblot. However, 25% of specimens with EIA R values of between 1.0 and 3.0 were not confirmed by either recombinant immunoblot assay (RIBA) or RNA PCR assay (false-positive specimens). A significant correlation (P less than 0.01) between increasing reactivity in the RIBA and positivity in the RNA PCR assay was found. The incidence of HCV viremia, as determined by the RNA PCR assay, was 73% for confirmed seropositive specimens, 33% for seropositive specimens with indeterminate RIBA results, 12% for seronegative specimens obtained from infected patients, and 2.0% for seronegative specimens obtained from uninfected blood donors. In contrast, serum transaminase testing did not correlate with the RNA PCR assay for HCV. Use of the EIA and immunoblot assay followed by RNA PCR testing will identify most patients who are viremic with HCV.
机译：丙型肝炎病毒（HCV）感染的临床和治疗决策取决于多种因素，包括过去感染的记录以及对可能受益于全身性干扰素抗病毒化疗的患者的鉴定。为了评估诊断实验室准确识别此类患者的能力，我们比较了血清转氨酶测定，两种HCV抗体测定（酶免疫测定[EIA]和免疫印迹）和基于聚合酶链反应（PCR）的HCV测定获得的结果RNA在我们基于大学的诊断病毒学实验室中使用一组连续提交的样品以及随机献血者群体的血清中的RNA。 HCV EIA中R值大于3.0的标本中有100％在确认性免疫印迹中呈阳性。但是，EIA R值在1.0到3.0之间的标本中有25％不能通过重组免疫印迹分析（RIBA）或RNA PCR分析来确定（假阳性标本）。发现RIBA中增加的反应性与RNA PCR分析中的阳性之间存在显着相关性（P小于0.01）。通过RNA PCR分析确定的HCV病毒血症的发生率：确诊的血清阳性标本为73％，RIBA结果不确定的血清阳性标本为33％，从感染患者获得的血清阴性标本为12％，从感染患者获得的血清阴性标本为2.0％未感染的献血者。相反，血清转氨酶测试与HCV的RNA PCR检测无关。使用EIA和免疫印迹测定，然后进行RNA PCR检测，将确定大多数丙型肝炎病毒血症患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号